Updated

Eli Lilly and Novo Nordisk are developing amylin-based drugs as a new biological approach to treating obesity and diabetes, aiming to build on the success of GLP-1 medications like Ozempic and Zepbound. The companies see amylin as another lever to pull in the rapidly growing weight-loss drug market. The push reflects intensifying competition between the two pharmaceutical giants to maintain leadership in obesity treatment as the GLP-1 market matures and rivals seek differentiated mechanisms to capture market share.